BIG PICTURE
Biosimilars save
the US healthcare
system an estimated
$5.4 billion each year*.
the US healthcare
system an estimated
$5.4 billion each year*.
Biocon Biologics is a proud leader in the advancement of biosimilars. As we
continue to drive innovation and invest in the
future, our mission is singularly focused on the
development, manufacturing, distribution,
and commercialization of the highest quality
biosimilars in the world.
Biocon Biologics
A fully integrated global biosimilars company, all in on biosimilars.
- A unique biosimilars portfolio spanning insulins, recombinant proteins, and monoclonal antibodies
- Cutting-edge science and research capabilities
- Experience built from successful global partnership with Mylan/Viatris
- Global-scale manufacturing with high standards of quality and compliance
biosimilars approved or in development
biosimilars launched across global
markets
countries where
biosimilars
are available
served globally by
Biocon Biologics'
biosimilars
* Estimates ofreductions in direct spending on biologic drugs from 2014 through
2024.
Reference: Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3.
Reference: Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3.
LEGACY OF SUCCESS
A long-standing presence in the biosimilars
industry
Biocon Biologics has emerged as a leader in biosimilars in the US and worldwide, providing
innovative and more affordable ways to treat diabetes, cancer, and autoimmune diseases. As a
result of its successful global partnership with Viatris, Biocon Biologics has broadened its
biosimilars capability from lab to market, commercializing the products it has been making for
years.
Founded to
improve access to
quality bioenzymes
improve access to
quality bioenzymes
Evolves into
bio-pharmaceuticals
bio-pharmaceuticals
First and only
company to
commercialize a
Pichia pastoris
derived rh-insulin
rh=recombinant human
company to
commercialize a
Pichia pastoris
derived rh-insulin
rh=recombinant human
Partners with
US-based Mylan to
co-develop
biosimilar
antibodies portfolio for global markets
US-based Mylan to
co-develop
biosimilar
antibodies portfolio for global markets
Launches world's
first trastuzumab
biosimilar
first trastuzumab
biosimilar
Solidifies foothold
in US and global
biosimilars space
in US and global
biosimilars space
Continues
partnership with
Viatris after
Mylan/Upjohn
merger
partnership with
Viatris after
Mylan/Upjohn
merger
Biocon Biologics
acquires Viatris'
global biosimilars
business to become
a fully integrated
biosimilars
company in the US
acquires Viatris'
global biosimilars
business to become
a fully integrated
biosimilars
company in the US
PORTFOLIO
Path-breaking
offerings with a focus
on the future.
offerings with a focus
on the future.
With a unique portfolio of monoclonal antibodies and insulins, Biocon Biologics is fully committed
to the long-term sustainability of global biosimilars access, investing more than $1 billion in
R&D
and global-scale manufacturing over the last 2 decades.
FULPHILA®
(pegfilgrastim-jmdb)
injection*
FIRST to receive
US approval - 2018
(5+ global markets)
OGIVRI®
(trastuzumab-dkst)
injection†‡
FIRST to receive
US approval - 2017
(5+ global markets) †Please see accompanying full US Prescribing Information, including BOXED WARNING.
Bevacizumab‡
Approved in EU 2021
(3+ global markets)
Filed for US approval
Denosumab‡
In global clinical trials
Pertuzumab‡
In global clinical trials
HULIO®
(adalimumab-fkjp)
injection†‡§¶
US approval 2020
Approved in EU 2018
(3+ global markets) †Please see accompanying full US Prescribing Information, including BOXED WARNING.
Etanercept§
Approved in EU 2020
(EU market)
Ustekinumab‡
In global clinical trials
SEMGLEE®
(insulin glargine-yfgn)
injection
FIRST US approval
of interchangeable
biosimilar - 2021
Approved in EU 2019
(6+ global markets)
Glargine 300U
In early development/
preclinical stage
Aspart
Approved in EU 2021 (2+ global markets)
Filed for US approval
Recombinant
human insulin*
Approved in
40+ global markets
Filed for US approval
Aflibercept#
Filed for US approval
In clinical trial OUS
7 assets
In early development/
preclinical stage
Biocon Biologics: an integrated player with proven end-to-end expertise
Research and
innovation
innovation
Product
Development
Development
Clinical
Trials
Trials
Global-scale
Manufacturing
Manufacturing
Regulatory
Sciences
Sciences
Commercialization
Portfolio
Oncology
Immunology
Diabetes
Bone Health
Ophthalmology
Our ongoing efforts continue to expand affordable
access to biosimilars for patients worldwide
access to biosimilars for patients worldwide
*Recombinant proteins. ‡Monoclonal antibodies. §In-licensed products. ¶Hulio will not be
marketed in the US
until July 2023. #Biocon Biologics has acquired the Viatris global rights to partnered asset.
EU: European Union. OUS: Outside the United States.
EU: European Union. OUS: Outside the United States.
To report an adverse event please call +1 833-986-1468